Ignite Proteomics Acquires Proprietary Laboratory Analysis for Proteomic Breast Cancer Assay
Feb. 19, 2025 – Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), is proud to announce the successful transfer of Theralink Technologies, Inc.’s Proprietary Laboratory Analysis (PLA) code 0249U. This code is significant as it is listed on the Medicare Clinical Laboratory Fee Schedule (CLFS) and is referenced in the Palmetto GBA MolDx “Proteomics Testing” article (A59636).
Integration of Proteomic Breast Cancer Assay Capability and Intellectual Property
With this acquisition, Ignite Proteomics has integrated both the laboratory capability and the owned and licensed intellectual property of the proteomic breast cancer assay into their operations. This move strengthens Ignite Proteomics’ position as a leader in the field of proteomic testing for cancer diagnosis.
Impact on the Healthcare Industry
The acquisition of the PLA code 0249U by Ignite Proteomics marks a significant step forward for the healthcare industry, particularly in the field of cancer diagnostics. Proteomics testing, which analyzes the expression of proteins in a sample, can provide valuable information for the diagnosis, prognosis, and treatment of various diseases, including breast cancer. This acquisition demonstrates Ignite Proteomics’ commitment to advancing proteomics testing and improving patient care.
Impact on Patients
For patients, this acquisition means that they may have access to more accurate and comprehensive cancer diagnoses. Proteomics testing can help identify cancer at an earlier stage, which can lead to more effective treatments and better outcomes. Additionally, the acquisition may lead to improved turnaround times and increased availability of proteomics testing, making it more accessible to a larger patient population.
Looking Forward
Ignite Proteomics is excited about the opportunities that this acquisition brings. With the integration of Theralink Technologies’ proteomic breast cancer assay, Ignite Proteomics can continue to innovate and advance proteomics testing. The company is committed to improving patient care and making proteomics testing more accessible and affordable.
Ignite Proteomics will continue to collaborate with healthcare providers and researchers to advance the field of proteomics testing and provide valuable insights into various diseases, including cancer. The company is dedicated to making a difference in the lives of patients and contributing to the overall improvement of healthcare.
- Ignite Proteomics acquires PLA code 0249U from Theralink Technologies, Inc.
- Code is listed on Medicare CLFS and referenced in Palmetto GBA MolDx article.
- Integrates laboratory capability and intellectual property of proteomic breast cancer assay.
- Strengthens Ignite Proteomics’ position as a leader in proteomics testing.
- Advances cancer diagnostics and improves patient care.
- Makes proteomics testing more accessible and affordable.
In conclusion, Ignite Proteomics’ acquisition of PLA code 0249U is a significant milestone for the company and the healthcare industry as a whole. This acquisition strengthens Ignite Proteomics’ position as a leader in proteomics testing and advances cancer diagnostics, ultimately improving patient care. With this acquisition, Ignite Proteomics is poised to continue innovating and making a difference in the lives of patients.
Ignite Proteomics is dedicated to collaborating with healthcare providers and researchers to advance the field of proteomics testing and provide valuable insights into various diseases, including cancer. The company’s commitment to improving patient care and making proteomics testing more accessible and affordable is a step in the right direction for the future of healthcare.
